/ /


Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.
FDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.
Comorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).
Body mass index is an independent predictor of metastasis and prostate cancer mortality after radical prostatectomy, according to results from a large, long-term single-institution study.
Men undergoing active surveillance for prostate cancer experienced levels of anxiety that were moderate, but that decreased over time, according to results of a large, prospective cohort study presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
“Active surveillance continues to gain traction as a management strategy for low-risk prostate cancer in the United States. However, barriers still exist and challenges remain for both the treating urologist and the patient,” writes J. Brantley Thrasher, MD.
New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
Multiparametric MRI, USPSTF’s updated PSA screening recommendation, and the landmark STAMPEDE and LATITUDE trials were among this year’s highlights in the peer-reviewed literature for prostate cancer, according to Leonard G. Gomella, MD; Stacy Loeb, MD, MS; and J. Brantley Thrasher, MD.
The overall use of active surveillance in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.
Tissue-based prognostic biomarker assays for prostate cancer are not robust to tumor multifocality and heterogeneity, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.